Arcis Biotechnology, a Daresbury, England, UK-based nucleic acid sample preparation solution provider, closed a £1.25m investment round.
Backers included existing and new investors.
The company, which is also raising an additional £0.5m, via specialist life sciences equity crowdfunding platform Capital Cell, will use the funds to invest further in R&D, product development, and to drive international business expansion.
Led by Peter Whitehurst, CEO, Arcis Biotechnology has developed its product portfolio based on proprietary, rapid, two-step nucleic acid extraction and preservation technology, from a range of biological samples. The company has an extensive patent portfolio covering extraction and preservation of DNA and RNA for downstream processing by qPCR, RT-qPCR and sequencing.